KIT and systemic mastocytosis: Nevertheless, in aggressive systemic mastocytosis and suspected well differentiated systemic mastocytosis cases, demonstration of absence of D816V is clinically important since cases with wild type-KIT and certain types of KIT mutations other than D816V may respond to imatinib therapy.19